# Chris Karp

> Chris Karp is a Series B investor at Bill & Melinda Gates Foundation backing Medical. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Bill & Melinda Gates Foundation](https://shizune.co/investors/profile/bill-melinda-gates-foundation)
- Location: Seattle, United States
- Total investments: 2
- Last investment: Mar 2020
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/chris-karp-6758bb103/

Chris Karp is a Series B investor at Bill & Melinda Gates Foundation in Seattle focused on Medical and Health Care. Chris Karp - Director, Global Health Discovery & Translational Sciences @ Bill & Melinda Gates Foundation

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Health Care | 1 | 50% |
| Biotechnology | 1 | 50% |
| Pharmaceutical | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Immunocore | Immunocore is focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The company’s expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100,entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems. Immunocore is a biotechnology company that specializes in the development of TCR bispecific immunotherapies. | $130M | Series B | Mar 02, 2020 |  |
| Immunocore | Immunocore is focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The company’s expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100,entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems. Immunocore is a biotechnology company that specializes in the development of TCR bispecific immunotherapies. | $40M | Series B |  |  |

2 of 2 investments shown.

## Co-investors
- [General Atlantic](https://shizune.co/investors/profile/general-atlantic) — VC Fund, 2 deals together
- [CCB International](https://shizune.co/investors/profile/ccb-international) — VC Fund, 1 deal together
- [Eli Lilly](https://shizune.co/investors/profile/eli-lilly) — VC Fund, 1 deal together
- [JDRF T1D Fund](https://shizune.co/investors/profile/jdrf-t1d-fund) — VC Fund, 1 deal together
- [Rock Springs Capital](https://shizune.co/investors/profile/rock-springs-capital) — VC Fund, 1 deal together
- [RTW Investments](https://shizune.co/investors/profile/rtw-investments-llc) — VC Fund, 1 deal together

## About Bill & Melinda Gates Foundation

VC Fund · New York, United States

The Bill & Melinda Gates Foundation is a grant-making foundation that supports initiatives in education, world health and population, and community giving in the Pacific Northwest. In its local region, the foundation promotes strategies and programs that help low income families.The Bill & Melinda Gates Foundation was co-founded by BillGates and Melinda Gates in 2000 and is based in Seattle, Washington, with regional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom. Its trustees are Bill and Melinda Gates, and Warren Buffett.

5 contacts available at Bill & Melinda Gates Foundation.

| Name | Title | Profile |
| --- | --- | --- |
| Bill Gates | Co-Chairman of the Board | https://shizune.co/investors/profile/bill-gates |
| Bill Gates | Co-Chairman of the Board | https://shizune.co/investors/profile/william-gates-sr |
| Brian Arbogast | Director of the Water, Sanitation & Hygiene Program | https://shizune.co/investors/profile/brian-arbogast |
| Chris Karp | Director, Global Health Discovery & Translational Sciences | https://shizune.co/investors/profile/chris-karp |
| Dan Hartman | Director, Integrated Development; Interim Director, Malaria. Global Health | https://shizune.co/investors/profile/dan-hartman |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Chris Karp invest in?

Chris Karp invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chris Karp last invest?

The most recent investment recorded for Chris Karp closed in Mar 2020. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co